Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Next Day Disclosure Returns - Share Buyback
2021-11-23
Next Day Disclosure Returns - Share Buyback
2021-11-19
Next Day Disclosure Returns - Share Buyback
2021-11-18
Voluntary Announcement - First Subject Dosed in the U.S. Phase I Trial for ASC43F Only Half a Month after IND Approval by the U.S. FDA
2021-11-18
Next Day Disclosure Returns - Share Buyback
2021-11-17
Next Day Disclosure Returns - Share Buyback
2021-11-16
Voluntary Announcement - Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee
2021-11-16
Next Day Disclosure Returns - Share Buyback
2021-11-15
Voluntary Announcement - China NMPA Approved Phase II And III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis
2021-11-15
Next Day Disclosure Returns - Share Buyback
2021-11-12

4

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1